Showing results (21-30 of 672) with videos related to
Sort By:
Pageof 68
Neuroscience Letters|August 17, 1992
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's diseaseE Sofic, K W Lange, K Jellinger, et al.Journal of Neurochemistry|November 1, 1990
Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defectP Lestienne, J Nelson, P Riederer, et al.Infusionstherapie Und Klinische Ernahrung|February 1, 1985
[Changes in and modulation of receptor activity in hepatic encephalopathy]E Kienzl, P Riederer, T Brücke, et al.Mechanisms of Ageing and Development|September 1, 1980
Levodopa in the treatment of (pre) senile dementiaK Jellinger, H Flament, P Riederer, et al.Acta Neuropathologica|July 21, 1999
The N-methyl-D-aspartate receptor channel blocker amantadine does not cause histopathological alterations in human brain tissueJ Kornhuber, K Jellinger, J Wiltfang, et al.Journal of Neural Transmission. Supplementum|January 1, 1983
General properties of 14C-L-Valine-binding to human brain tissueP Riederer, E Kienzl, K Jellinger, et al.Journal of Neural Transmission. Supplementum|January 1, 1978
Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosisP Riederer, W D Rausch, W Birkmayer, et al.Journal of Neurochemistry|January 1, 1988
Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agentsW D Rausch, Y Hirata, T Nagatsu, et al.Journal of Neurochemistry|March 1, 1991
Selective increase of iron in substantia nigra zona compacta of parkinsonian brainsE Sofic, W Paulus, K Jellinger, et al.Journal of Neural Transmission|January 1, 1978
Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administrationG P Reynolds, P Riederer, M Sandler, et al.Pageof 68